| Identification | Back Directory | [Name]
L-Threoninamide, N2,N6-bis[2-[[[(8β)-6-propylergolin-8-yl]methyl]thio]acetyl]-D-lysyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-(2S)-2-aminobutanoyl-L-cysteinyl-, cyclic (2→7)-disulfide | [CAS]
778630-77-6 | [Synonyms]
TBR-760
BIM-23A760
Onzigolide
L-Threoninamide, N2,N6-bis[2-[[[(8β)-6-propylergolin-8-yl]methyl]thio]acetyl]-D-lysyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-(2S)-2-aminobutanoyl-L-cysteinyl-, cyclic (2→7)-disulfide | [Molecular Formula]
C86H116N16O12S4 | [MOL File]
778630-77-6.mol | [Molecular Weight]
1694.21 |
| Hazard Information | Back Directory | [Uses]
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors[1][2]. | [IC 50]
SSTR2 | [References]
[1] Halem HA, et al. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101. DOI:10.1210/endocr/bqaa101
[2] Cuny T, et al. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary. 2021 Jun;24(3):351-358. DOI:10.1007/s11102-020-01113-4 |
|
|